论文部分内容阅读
2003年10月,财政部和国家税务总局发布了财税[2003]222号《关于调整出口货物退税率的通知》。根据有关规定,我国大宗品种原料药出口退税率下调2至4个百分点,这一调整政策曾被一些原料药企业称为继产品降价、原材料能源价格上涨后的“第三重压力”。而事实证明此次退税率的调整对医药行业的出口影响并不大。据中国医药保健品进出口商会的统计资料显示,2004年化学原料药类出口数量同比增长35.8%,出口金额同比增长88%。今年头三个月我国化学原料药出口总额为18.15亿美元,同比增长32.84%,实现贸易顺差4.74亿美元,延续了良好的贸易态势。
In October 2003, the Ministry of Finance and the State Administration of Taxation issued Caishui [2003] No. 222 Notice on Adjusting the Rate of Refund of Exported Goods. According to the relevant regulations, the export tax rebate rate of bulk raw materials for medicines in China will be reduced by 2 to 4 percentage points. This adjustment policy has been called by some raw material drug companies as the “third pressure” after prices of raw materials and energy prices of raw materials go up. The fact that the adjustment of the tax rebate rate on the export of the pharmaceutical industry has little effect. According to statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, the volume of export of chemical raw materials and drugs increased by 35.8% and 88% respectively over the same period of last year. In the first three months of this year, China’s total export volume of chemical raw materials was 1.815 billion U.S. dollars, up 32.84 percent over the same period of the previous year and achieved a trade surplus of 474 million U.S. dollars, continuing a good trade trend.